@article{11b48a429f19411e807ebe07286459f7,
title = "Cost-effectiveness of polatuzumab vedotin in combination with chemoimmunotherapy (pola-R-CHP) in previously untreated diffuse large B-cell lymphoma in Germany",
keywords = "DLBCL, R-CHOP, cost-effectiveness analysis, lymphoma, pola-R-CHP, Lymphoma, Large B-Cell, Diffuse/therapy, Immunoconjugates/therapeutic use, Humans, Cost-Benefit Analysis, Antibodies, Monoclonal/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/adverse effects",
author = "Swetha Kambhampati and Evgenii Shumilov and Monica Saumoy and Herrera, \{Alex F.\} and Herv{\'e} Tilly and Georg Lenz and Thiruvengadam, \{Nikhil R.\}",
note = "Publisher Copyright: {\textcopyright} 2023 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley \& Sons Ltd.",
year = "2023",
month = aug,
doi = "10.1111/bjh.18869",
language = "English",
volume = "202",
pages = "771--775",
journal = "British Journal of Haematology",
issn = "0007-1048",
number = "4",
}